Bioverativ

Bioverativ is a global biotechnology company dedicated to the research, development, and commercialization of innovative therapies for hemophilia and other rare blood disorders. The company was established in 2016 as a spin-off from Biogen, a multinational biotechnology company based in the United States. Bioverativ's mission is to create progress and make a positive difference in the lives of people living with hemophilia and other rare blood disorders.

History

Bioverativ was officially launched in 2016, following its separation from Biogen. The company was created with the aim of focusing on the research and development of therapies for rare blood disorders, with a particular emphasis on hemophilia. In 2018, Bioverativ was acquired by Sanofi, a global pharmaceutical company, for $11.6 billion. This acquisition expanded Sanofi's presence in specialty care and strengthened its leadership in rare diseases.

Products and Services

Bioverativ's product portfolio includes two extended half-life therapies, Eloctate and Alprolix, for the treatment of hemophilia A and B respectively. These therapies are designed to provide long-lasting protection against bleeding episodes with a reduced dosing frequency.

In addition to its marketed products, Bioverativ has a robust pipeline of investigational therapies for the treatment of hemophilia and other rare blood disorders. These include BIVV001, a novel investigational therapy for hemophilia A, and BIVV002, an investigational gene therapy for hemophilia B.

Research and Development

Bioverativ's research and development efforts are focused on advancing the understanding of the biology of blood and rare diseases, and leveraging this knowledge to develop innovative therapies. The company collaborates with academic institutions, clinical investigators, and patient advocacy groups to accelerate the discovery and development of new treatments.

Impact

Bioverativ's work has had a significant impact on the lives of people living with hemophilia and other rare blood disorders. The company's therapies have improved the quality of life for patients by reducing the frequency of bleeding episodes and the burden of treatment. Furthermore, Bioverativ's research and development efforts have contributed to the advancement of scientific understanding in the field of hematology.

‎